Skip to content

Research on the Intervention Effect of Camellia Oil Diet on the High Risk Group of Atherosclerosis

Research on the Intervention Effect of Camellia Oil Diet on the High Risk Group of Atherosclerosis

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100047980
Enrollment
Unknown
Registered
2021-06-28
Start date
2021-07-01
Completion date
Unknown
Last updated
2022-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerosis

Interventions

experimental group:Drinking Camellia oil, intake = body weight (kg)× dose (0.22ml)

Sponsors

The Fifth Affiliated Hospital of Zunyi Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Middle-risk population (5.0%-9.9%) and low-risk population (less than 5.0%) were screened by 10-year ASCVD Morbidity Risk Assessment Table; 2. Adherence to the experimental dietary intervention; 3. Aged from 35 to 65 years; 4. Those who agree to participate in clinical research and sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Those who have been diagnosed as ASCVD (very high risk group); 2. Those who meet one of the following criteria (high risk group) (1)1.8 mmol/l 40 years); (2) Individuals with very high levels of individual risk factors, they included: 1) LDL-C level >=4.9 mmol/l (190 MG/DL) or total cholesterol (TC) level >=7.2 mmol/l (280 MG/DL); 2) Class 3 hypertension; 3) Heavy smoking (>=30 cigarettes/day) . (3) Those with any of the following risk factors: 1) Systolic blood pressure >=160mmhg or diastolic blood pressure >=100mmhg; 2) NON-HDL-C >=5.2 mmol/l (200mg/dl); 3) HDL-C =28kg/m2; 5) Smoking; 3. Ultrasound of the carotid artery showed severe obstruction of blood flow or absence of plaque formation due to plaque in the lumen; 4. Complicated with severe cardiopulmonary insufficiency and Severe Arrhythmia (rapid atrial fibrillation, atrial flutter, paroxysmal ventricular Tachycardia, etc.); 5. Severe hepatic and renal dysfunction; 6. Patients with systemic immune disease, severe infection, malignant tumor, acute coronary syndrome, acute stroke. 7. Allergic constitution or allergic to multiple drugs; 8. Those who have been treated with similar drugs in the past 3 months, and the efficacy of the drugs is difficult to judge; 9. Participate in other clinical research.

Design outcomes

Primary

MeasureTime frame
Blood routine;Lipid Metabolism Index;Physical indicators;Comprehensive Metabolic Panel;Carotid ultrasound measurement;

Countries

China

Contacts

Public ContactCui Guozhen

Zhuhai Campus, Zunyi Medical University

cgzum@hotmail.com+86 13750035436

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026